Kani Bilginaylar1, Asli Aykac2, Serkan Sayiner3,4, Hanife Özkayalar5, Ahmet Özer Şehirli6. 1. Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Final International University, Nicosia, Cyprus. kani_blgnylr@hotmail.com. 2. Department of Biophysics, Faculty of Medicine, Near East University, Nicosia, Cyprus. 3. Department of Biochemistry, Faculty of Veterinary Medicine, Near East University, Nicosia, Cyprus. 4. Diagnostic Laboratory, Animal Hospital, Faculty of Veterinary Medicine, Near East University, Nicosia, Cyprus. 5. Department of Pathology, Faculty of Medicine, Near East University, Nicosia, Cyprus. 6. Departments of Pharmacology, Faculty of Dentistry, Near East University, Nicosia, Cyprus.
Abstract
BACKGROUND: Methotrexate (MTX), a chemotherapeutic agent, is known to cause oral mucositis. Chitosan has been shown to have a protective effect in inflammatory animal models. This research aimed to examine the protective effect of chitosan against oral mucositis caused by MTX. METHODS AND RESULTS: Wistar albino rats were randomly divided into three groups. Control (n = 8), (saline via oral gavage for 5 days), MTX (n = 8), (60 mg/kg single dose MTX intraperitoneally on the 1st day and for the following 4 days saline via oral gavage), and MTX + chitosan (n = 8), (1st day single dose 60 mg/kg MTX intraperitoneally and followed with 200 mg/kg chitosan via oral gavage for 4 days). After 24 h of the last dose, the animals were euthanised. Blood, tongue, buccal and palatal mucosa tissues were collected. Serum interleukin 1-beta (IL1-β), tumour necrosis factor-alpha (TNF-α), matrix metalloproteinase (MMP-1, and MMP-2) activities, tissue bcl-2/bax ratio and the expression of caspase-3 (casp-3), and casp-9 were detected. The tissues were also examined histologically. Serum TNF-α, IL1-β, MMP-1 and MMP-2 activities and tissue casp-3 and casp-9 activities significantly increased but the bcl-2/bax ratio significantly decreased in the MTX group compared those of the control group. Histologically, diffuse inflammatory cells were observed in MTX group. However, In the MTX + chitosan group, all the values were close to those of the control group. CONCLUSION: It was demonstrated that chitosan has a protective effect against oral mucosal damage caused by MTX. Thus, it may be a candidate agent against MTX induced oral mucositis.
BACKGROUND: Methotrexate (MTX), a chemotherapeutic agent, is known to cause oral mucositis. Chitosan has been shown to have a protective effect in inflammatory animal models. This research aimed to examine the protective effect of chitosan against oral mucositis caused by MTX. METHODS AND RESULTS: Wistar albino rats were randomly divided into three groups. Control (n = 8), (saline via oral gavage for 5 days), MTX (n = 8), (60 mg/kg single dose MTX intraperitoneally on the 1st day and for the following 4 days saline via oral gavage), and MTX + chitosan (n = 8), (1st day single dose 60 mg/kg MTX intraperitoneally and followed with 200 mg/kg chitosan via oral gavage for 4 days). After 24 h of the last dose, the animals were euthanised. Blood, tongue, buccal and palatal mucosa tissues were collected. Serum interleukin 1-beta (IL1-β), tumour necrosis factor-alpha (TNF-α), matrix metalloproteinase (MMP-1, and MMP-2) activities, tissue bcl-2/bax ratio and the expression of caspase-3 (casp-3), and casp-9 were detected. The tissues were also examined histologically. Serum TNF-α, IL1-β, MMP-1 and MMP-2 activities and tissue casp-3 and casp-9 activities significantly increased but the bcl-2/bax ratio significantly decreased in the MTX group compared those of the control group. Histologically, diffuse inflammatory cells were observed in MTX group. However, In the MTX + chitosan group, all the values were close to those of the control group. CONCLUSION: It was demonstrated that chitosan has a protective effect against oral mucosal damage caused by MTX. Thus, it may be a candidate agent against MTX induced oral mucositis.
Authors: Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2013-04-21 Impact factor: 3.603
Authors: Joanne M Bowen; Rachel J Gibson; Anna Tsykin; Andrea M Stringer; Richard M Logan; Dorothy M K Keefe Journal: Int J Cancer Date: 2007-10-15 Impact factor: 7.396
Authors: Ann S J Yeoh; Rachel J Gibson; Eric E K Yeoh; Joanne M Bowen; Andrea M Stringer; Kar A Giam; Dorothy M K Keefe Journal: Mol Cancer Ther Date: 2007-08 Impact factor: 6.261
Authors: Fernando Barbosa; José Eduardo Tanus-Santos; Raquel Fernanda Gerlach; Patrick J Parsons Journal: Environ Health Perspect Date: 2005-12 Impact factor: 9.031
Authors: Marika Cinausero; Giuseppe Aprile; Paola Ermacora; Debora Basile; Maria G Vitale; Valentina Fanotto; Giuseppe Parisi; Lorenzo Calvetti; Stephen T Sonis Journal: Front Pharmacol Date: 2017-06-08 Impact factor: 5.810
Authors: Sali Al-Ansari; Judith A E M Zecha; Andrei Barasch; Jan de Lange; Fred R Rozema; Judith E Raber-Durlacher Journal: Curr Oral Health Rep Date: 2015-10-19